AR033151A1 - Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares - Google Patents

Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares

Info

Publication number
AR033151A1
AR033151A1 ARP020101334A ARP020101334A AR033151A1 AR 033151 A1 AR033151 A1 AR 033151A1 AR P020101334 A ARP020101334 A AR P020101334A AR P020101334 A ARP020101334 A AR P020101334A AR 033151 A1 AR033151 A1 AR 033151A1
Authority
AR
Argentina
Prior art keywords
agent
inflammatory
present agent
ophthalmic treatment
eye
Prior art date
Application number
ARP020101334A
Other languages
English (en)
Original Assignee
Sucampo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Pharmaceuticals Inc filed Critical Sucampo Pharmaceuticals Inc
Publication of AR033151A1 publication Critical patent/AR033151A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente provee un agente para el tratamiento oftálmico topico de un ser humano para enfermedades inflamatorias oculares, que contiene un compuesto como se muestra en la formula general (1) o sus sales farmacéuticamente aceptables como el ingrediente activo en la concentracion de 0,01% a 0,1%. El presente agente para el tratamiento oftálmico topico muestra continuamente efectos antiinflamatorios oculares superiores mediante la administracion topica en una dosis baja al ojo de un ser humano que tiene enfermedades inflamatorias oculares. El presente agente es efectivo para síntomas causados por la enfermedad inflamatoria ocular tales como picazon, ardor, edema, ulcera, etc. El presente agente también es efectivo para un sujeto en el cual los agentes antiinflamatorios no muestran un efecto de mejora (por ej., esteroides y ciclosporinas). El presente agente también es efectivo para un sujeto para el cual no se pueden usar otros agentes antinflamatorios (por ej., contraindicacion de esteroides). El presente agente es muy util especialmente por la razon de que muestra suficientes efectos mediante la administracion topica al ojo durante una a cuatro veces.
ARP020101334A 2001-04-12 2002-04-11 Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares AR033151A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28316901P 2001-04-12 2001-04-12

Publications (1)

Publication Number Publication Date
AR033151A1 true AR033151A1 (es) 2003-12-03

Family

ID=23084835

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101334A AR033151A1 (es) 2001-04-12 2002-04-11 Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares

Country Status (12)

Country Link
US (1) US20020187998A1 (es)
EP (1) EP1379247A1 (es)
JP (1) JP2004529928A (es)
KR (1) KR20040007494A (es)
CN (1) CN1503671A (es)
AR (1) AR033151A1 (es)
BR (1) BR0208939A (es)
CA (1) CA2445508A1 (es)
MX (1) MXPA03009273A (es)
NO (1) NO20034560L (es)
NZ (1) NZ529255A (es)
WO (1) WO2002085359A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ530845A (en) 2001-07-06 2006-03-31 Sucampo Ag Composition for topical administration
KR20040066825A (ko) * 2001-11-19 2004-07-27 노파르티스 아게 아스코마이신의 안검염 치료 용도
US20050239813A1 (en) * 2002-08-09 2005-10-27 Sucampo Pharmaceuticals Inc. Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AR042890A1 (es) * 2003-01-16 2005-07-06 Sucampo Pharmaceuticals Inc Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8222271B2 (en) * 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam
WO2015188126A1 (en) * 2014-06-06 2015-12-10 The Schepens Eye Research Institute, Inc. Compositions and methods for treating tumors and immune based inflammatory diseases
PL3470059T3 (pl) * 2015-01-26 2020-11-30 Bausch & Lomb Incorporated Kompozycja zawiesiny okulistycznej
KR101710412B1 (ko) 2015-09-15 2017-02-27 인제대학교 산학협력단 Ycg063을 유효성분으로 함유하는 염증성 안구질환 예방 또는 치료용 약학조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
AU635286B2 (en) * 1989-07-05 1993-03-18 Astellas Pharma Inc. Aqueous liquid composition for external use
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
KR100237715B1 (ko) * 1991-04-26 2000-02-01 후지야마 아키라 안과질환에 대한 마크로라이드 화합물의 용도
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen

Also Published As

Publication number Publication date
US20020187998A1 (en) 2002-12-12
JP2004529928A (ja) 2004-09-30
KR20040007494A (ko) 2004-01-24
BR0208939A (pt) 2004-04-20
NZ529255A (en) 2006-09-29
NO20034560L (no) 2003-12-09
EP1379247A1 (en) 2004-01-14
NO20034560D0 (no) 2003-10-10
CN1503671A (zh) 2004-06-09
CA2445508A1 (en) 2002-10-31
MXPA03009273A (es) 2004-02-12
WO2002085359A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
AR033151A1 (es) Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
MX2022007276A (es) Tratamiento de la esclerosis amiotrofica lateral y enfermedades relacionadas.
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200602130A1 (ru) Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов
AR032556A1 (es) Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
EA200702445A1 (ru) Соединения тиазола и способы их применения
ES2069410T3 (es) Nuevos derivados del acido hidroxamico y n-hidroxiurea y su uso.
BR0312232A (pt) Inibidores de caspases e seus usos
CR6963A (es) Formas de sal de amida de acido 3.(4-bromo-2,6-difluoro-benciloxi)-5-(3-(4-piprolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y metodo de produccion
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
DK0868909T3 (da) Opthalmisk bæreropløsning
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
BR9914419A (pt) Terapia para melhoria da percepção
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
JP2004529928A5 (es)
ES2393927T5 (es) Composiciones tópicas
MX2023004537A (es) Compuestos y metodos para el tratamiento de trastornos oculares.
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
ES2215493T1 (es) Agente farmacologico que comprende acido picolinico, acido fusarico y sus derivados.
AR034866A1 (es) Comprimido que comprende cetirizina y pseudoefedrina
ES2341789T3 (es) Composiciones oftalmicas y metodos de uso de las mismas.
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal